#USA #Alpheus Medical #Chanhassen #Glioblastoma #PoMA therapy

Alpheus Medical's New Initiative Against Butterfly Glioblastoma

Alpheus Medical, Inc., a biotechnology firm committed to clinical development, has announced the launch of a groundbreaking clinical trial targeting butterfly glioblastoma – a particularly aggressive type of brain cancer that jeopardizes both hemispheres of the brain. The trial, known as the Alpheus Butterfly trial (NCT07862647), aims to evaluate the efficacy of the Porphyrin Metabolite Activation (PoMA™) therapy, which has shown promise in addressing the unique challenges posed by this cancer.

Understanding Butterfly Glioblastoma

Butterfly glioblastoma is notorious for its rapidly progressive nature and its tendency to spread across the brain's midline, complicating surgical interventions and limiting many standard treatment options. The median survival rate for patients diagnosed with this form of tumor sits alarmingly between three to six months. Traditional clinical trials often exclude these patients due to the bilateral spread of the disease, which leaves individuals facing few options for effective treatment.

Introducing PoMA Therapy

The PoMA therapy represents a novel approach that combines the tumor-localizing agent 5-aminolevulinic acid (5-ALA) with low-intensity defocused ultrasound. During the treatment, 5-ALA is administered orally, allowing the metabolite protoporphyrin IX (PpIX) to accumulate preferentially within tumor cells. This accumulation is then activated using ultrasound technology, making the entire process possible in an outpatient setting, while the patients remain awake. This non-invasive approach also allows for repetition.

Enrollment Details

Patients newly diagnosed with butterfly glioblastoma are encouraged to participate in this trial, which requires them to enroll before commencing standard chemoradiation treatments. Clinicians, patients, and caregivers interested in learning more about eligibility and the logistics of the trial can visit www.BrainCancerTrial.com.

David Reardon, MD, the Chief of the Division of Neuro-Oncology at Dana-Farber Cancer Institute, emphasized the significance of this trial in the landscape of treatment options available for this patient demographic. He noted, "Patients with butterfly glioblastoma present some of the most significant challenges. Alpheus' innovative strategy seeks to address the bilateral nature of the tumors while maintaining a targeted treatment methodology."

Clinical Centers and Ongoing Support

The multi-center study will initially conduct patient enrollment at the Dent Neurologic Institute in Buffalo, New York, with plans to expand to additional clinical centers across the United States shortly. Alpheus Medical has secured further financial backing to not only support the ongoing Butterfly GBM study but also to advance the broader development of the PoMA therapy.

Vijay Agarwal, MD, CEO of Alpheus Medical, remarked on the urgency of this clinical trial, stating, "The diagnosis of butterfly glioblastoma is one that carries tragic implications. Our study has been meticulously designed to align with the disease's characteristics and deliver a non-invasive solution that can effectively target both hemispheres of the brain. We are reaching out to both patients and physicians to make them aware of this trial while emphasizing the importance of early contact."

In Summary

The Alpheus Butterfly trial hopes to unlock new possibilities for patients battling butterfly glioblastoma by exploring the potential of PoMA therapy. With the trial now open for enrollment, patients and caregivers are urged to take action and learn more about this pioneering treatment opportunity. For additional information regarding eligibility or to find out more about the clinical centers involved, don't hesitate to visit www.BrainCancerTrial.com. For more insights about Alpheus Medical and its innovative solutions that target glioblastoma, check out their official site at www.alpheusmedical.com.